Ranolazine and late cardiac sodium current – a therapeutic target for angina, arrhythmia and more? | Zendy

Makielski Jonathan C | Zendy; Valdivia Carmen R | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Ranolazine and late cardiac sodium current – a therapeutic target for angina, arrhythmia and more?

Author(s) -

Makielski Jonathan C,

Valdivia Carmen R

Publication year - 2006

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1038/sj.bjp.0706713

Subject(s) - ranolazine , medicine , angina , cardiology , long qt syndrome , cardiac arrhythmia , pharmacology , qt interval , atrial fibrillation , myocardial infarction

Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general. British Journal of Pharmacology (2006) 148 , 4–6. doi: 10.1038/sj.bjp.0706713

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research